Atezolizumab

Atezolizumab · PD-L1 inhibitor

Immunotherapy for NSCLC, SCLC, hepatocellular carcinoma, melanoma and other solid tumors

1200mg IV infusion Every 3 weeks

Therapeutic Areas

Oncology

Marketed Products

Atezolizumab

Modality

Atezolizumab

Core Products

Osimertinib · 3rd-generation EGFR TKI

Palbociclib · CDK4/6 inhibitor

Bevacizumab · Anti-VEGF monoclonal antibody

Creating a Healthier Future Together

Explore our innovative products and pipeline, and see how Poseidon brings hope to patients worldwide